Scimitar Equity Blog

In 2 groundbreaking studies, doctors have used stem cells from bone marrow to help heal children Read more…

SCT or TSX VENTURE: SSS’s IRB (Institutional Review Board) at the University of Calgary/Foothills Hospital has approved the SCT-sponsored investigator lead Phase IIa study Read more…

Net income was $1.7 M and $0.05 per diluted common share. Read more…

Adult stem cells have been identified to have cancer suppressive activity in a … preclinical study. Read more…

Scientists at the National Health Research Institutes (NHRI, TAIPEI, Taiwan) successfully turned cells in the umbilical vein into “all-purpose” induced pluripotent stem cells (iPS).

Read more…

CYTX received US Patent No. 7,771,716 (“716” patent) for Celution® System based methods of treating musculoskeletal disorders such as spinal disc disease. Read more…

KOOL’s Board of Directors has unanimously approved a reverse split of its common stock at a ratio of 1 new share for each 4 existing shares, effective on 8/26/10. Read more…

NBS has entered into a sponsored research agreement (SRA) with the Schepens Eye Research Institute, Read more…

Q2/10 net loss was $2.9 M or $0.00 per share on fully diluted shares of 884 M shares; with the 1^st half of FY10 net loss was $15 M or $0.02 on fully diluted shares of 708.5 M shares. Read more…

The FDA is seeking to stop a Colorado company from offering an autologous stem cell therapy for arthritic knees and other orthopedic problems Read more…